April 3, 2018 / 5:07 AM / 3 months ago

BRIEF-‍EMA To Review Cemiplimab As Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma​

April 3 (Reuters) - Regeneron Pharmaceuticals Inc:

* ‍EMA TO REVIEW CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA​

* ‍EUROPEAN MEDICINES AGENCY HAS ACCEPTED FOR REVIEW MARKETING AUTHORIZATION APPLICATION (MAA) FOR CEMIPLIMAB​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below